Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are observing how men with metastatic hormone-sensitive prostate cancer mHSPC respond to treatment with darolutamide combined with androgen deprivation therapy ADT, with or without the chemotherapy drug docetaxel. This international, open-label, multi-cohort study aims to understand the real-world effectiveness and safety of these treatments in routine medical practice. The study will enroll about 1,600 male patients primarily from Europe, focusing on those already decided to receive darolutamide before joining the study. Participants will be divided into two groups one receiving darolutamide plus ADT and docetaxel triplet therapy, and the other receiving darolutamide plus ADT without docetaxel doublet therapy. Treatment is given according to local standard care and chosen by the treating physician. No additional study-specific treatments or procedures are required, as data is collected during routine care visits over the study period. During the study, researchers will collect data on prostate-specific antigen PSA levels, survival rates, time to new treatments, progression of disease, adverse events, quality of life, and other clinical information. Data collection is done via electronic records during regular doctor visits with no extra tests beyond standard care. The study will last up to four years with periodic analyses to help improve understanding of darolutamide use in everyday clinical settings.